OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and Efficacy of Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma and Impaired Liver Function: A Systematic Review and Meta-Analysis
Andrea Pasta, Francesco Calabrese, Ariel Jaffe, et al.
Liver Cancer (2023) Vol. 13, Iss. 3, pp. 235-245
Open Access | Times Cited: 6
Andrea Pasta, Francesco Calabrese, Ariel Jaffe, et al.
Liver Cancer (2023) Vol. 13, Iss. 3, pp. 235-245
Open Access | Times Cited: 6
Showing 6 citing articles:
Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis
Yu-Chun Hsu, Po‐Ting Lin, Wei Teng, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3458-3458
Open Access | Times Cited: 4
Yu-Chun Hsu, Po‐Ting Lin, Wei Teng, et al.
Cancers (2024) Vol. 16, Iss. 20, pp. 3458-3458
Open Access | Times Cited: 4
Proper assessment and prognostication of patients with hepatocellular carcinoma
Edoardo G. Giannini
Clinical Liver Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Edoardo G. Giannini
Clinical Liver Disease (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Heterogeneity in adverse events related to Atezolizumab-Bevacizumab for hepatocellular carcinoma reported in real-life studies
Claudia Campani, D C Pallas, Sabrina Sidali, et al.
JHEP Reports (2024) Vol. 6, Iss. 11, pp. 101190-101190
Open Access | Times Cited: 1
Claudia Campani, D C Pallas, Sabrina Sidali, et al.
JHEP Reports (2024) Vol. 6, Iss. 11, pp. 101190-101190
Open Access | Times Cited: 1
The assessment of impaired liver function and prognosis in hepatocellular carcinoma
Roxana Pantea, Jan Bednarsch, Sophia M. Schmitz, et al.
Expert Review of Gastroenterology & Hepatology (2024)
Open Access | Times Cited: 1
Roxana Pantea, Jan Bednarsch, Sophia M. Schmitz, et al.
Expert Review of Gastroenterology & Hepatology (2024)
Open Access | Times Cited: 1
Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response
Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, et al.
Current Oncology (2024) Vol. 31, Iss. 10, pp. 6218-6231
Open Access
Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, et al.
Current Oncology (2024) Vol. 31, Iss. 10, pp. 6218-6231
Open Access
May we actually help clinicians select the best systemic treatment for patients with intermediate‐stage hepatocellular carcinoma?
Edoardo G. Giannini, Mario Strazzabosco
Liver International (2024) Vol. 44, Iss. 2, pp. 272-274
Open Access
Edoardo G. Giannini, Mario Strazzabosco
Liver International (2024) Vol. 44, Iss. 2, pp. 272-274
Open Access
